|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-1.51/--
|
企业价值
170.90M
|
资产负债 |
每股账面净值
-5.85
|
现金流量 |
现金流量率
--
|
损益表 |
收益
0
|
每股收益
--
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/11/10 15:06 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, thatlead to tumor cell survival, growth, migration, and invasion. |